Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 5,000 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $16.07, for a total transaction of $80,350.00. Following the transaction, the insider now directly owns 997,688 shares of the company's stock, valued at $16,032,846.16. The trade was a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Enliven Therapeutics Stock Down 1.1 %
NASDAQ ELVN opened at $17.77 on Thursday. The company has a 50-day moving average price of $19.51 and a 200-day moving average price of $22.84. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $30.03. The firm has a market capitalization of $870.80 million, a P/E ratio of -9.35 and a beta of 1.03.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.
Hedge Funds Weigh In On Enliven Therapeutics
A number of institutional investors have recently bought and sold shares of ELVN. Polar Capital Holdings Plc increased its position in Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after buying an additional 1,739,668 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of Enliven Therapeutics during the 4th quarter valued at approximately $15,106,000. Lord Abbett & CO. LLC purchased a new stake in Enliven Therapeutics in the 3rd quarter worth approximately $8,199,000. Janus Henderson Group PLC raised its stake in Enliven Therapeutics by 27.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after acquiring an additional 290,153 shares during the period. Finally, FMR LLC lifted its holdings in Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after purchasing an additional 199,692 shares in the last quarter. 95.08% of the stock is owned by institutional investors.
Analyst Ratings Changes
Separately, HC Wainwright boosted their target price on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 21st.
View Our Latest Research Report on ELVN
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
